GlyHealth-IBD is the most advanced of our disease-specific GlyHealth variants. It is a prognostic and predictive biomarker of inflammatory bowel disease (IBD).The test is being designed to support clinical decision-making by gastroenterologists caring for IBD patients and as a complementary biomarker to enhance clinical trials for anti-inflammatory drugs for IBD.
The glycomics patterns we measure in GlyHealth-IBD are early-warning, sub-clinical, prodromal signals of future Inflammatory Bowel Disease flares.
Preliminary studies on over 400 patients showed that GlyHealth-IBD can, from a small (0.2ml) sample of blood, reliably measure:
- The severity of an IBD patient’s disease now,
- The likely future course of their disease and
- The likelihood they would need future treatment escalation up to 18 months from the time of testing.